CRA consultants were engaged in connection with a class action in which branded and generic pharmaceutical manufacturers were alleged to have delayed market entry of a generic form of a popular drug. CRA staff analyzed whether there was sufficient evidence to demonstrate that direct purchasers (e.g., wholesalers and medical facilities) suffered a common impact from the alleged activities. This analysis combined economic theory, quantitative research and estimation, and industry knowledge to demonstrate significant differences among members of the proposed class. Following a hearing on class certification, the plaintiffs withdrew their complaint.
Antitrust implications of the build vs. buy playbook in the AI era
The rapid growth of artificial intelligence (AI) makes the build-versus-buy question particularly important. AI markets are evolving quickly, and firms must...